References in periodicals archive ?
David Dodd, Chairman, CEO at Aeterna Zentaris stated, The implementation of our own sales force and the field selling of ASCEND's EstroGel, mark an important step in our strategy of transitioning into a commercially operating specialty biopharmaceutical company, while the FDA continues its active NDA review for the approval of MacrilenTM in the evaluation of AGHD.
Jay Bua, President & CEO at ASCEND Therapeutics stated, We are very pleased to be joining forces with Aeterna Zentaris as it will immediately extend our share of voice of the EstroGel franchise, and also open opportunities to future co-promotional activities.
It will immediately extend our share of voice of the EstroGel franchise as well as open opportunities to future co-promotional activities.
a diversified sales and marketing services provider to the biopharmaceutical industry, today announced that it has entered into a two-year agreement with Ascend Therapeutics, to promote their estrogen replacement therapy product, EstroGel, to the obstetrician/gynecologist market.